Conditional survival probability of distant-metastatic hepatocellular carcinoma: A population-based study

Table 3 Six-month conditional overall survival rates of patients with distant-metastatic hepatocellular carcinoma

Characteristics		Overall survival (months after diagnosis)
		0	d	2	d	4	d	6	d
Overall		32.79		41.05		47.48		53.31
Age, yr
< 55	30.69		42.39		59.26		64.45
55-65	33.86	0.07	39.96	-0.05	44.03	-0.30	45.78	-0.37
≥ 65	32.64	0.04	41.65	-0.02	49.58	-0.19	56.99	-0.15
Gender
Female	34.64		43.92		52.4		55.63
Male	32.38	-0.05	40.42	-0.07	46.37	-0.12	52.75	-0.06
Race
Black	33.03		41.07		48.04		51.95
White	34.35	0.03	42.77	0.03	48.1	0.001	54.56	0.05
Other	27.17	-0.12	34.55	-0.13	44.34	-0.07	49.06	-0.06
Marital status
Married	32.59		40.58		46.51		54.99
Single	32.99	0.01	42.24	0.03	51.3	0.10	52.08	-0.06
Separated	32.96	0.01	40.71	0.00	45.57	-0.02	51.27	-0.07
AFP expression
Positive	30.77		38.99		44.09		49.63
Negative	43.69	0.28	50.46	0.23	62.1	0.36	67.32	0.35
Tumor size
≤ 5 cm	38.43		50.31		62.75		60.63
> 5 cm	30.67	-0.17	37.48	-0.26	39.59	-0.46	49.85	-0.22
T stage
T1	39.82		49.18		56.84		60.72
T2	36.94	-0.06	49.78	0.01	57	0.003	55.68	-0.10
T3	28.86	-0.23	34.84	-0.29	41.77	-0.30	49.69	-0.22
T4	31.63	-0.17	40.2	-0.18	33.72	-0.46	46.16	-0.29
N stage
N0	34.58		43.29		50.08		57.11
N1	28.87	-0.12	35.65	-0.16	40.76	-0.19	43.26	-0.28
Surgery
No	30.65		38.31		44.61		50.83
Yes	69.51	0.83	73.97	0.73	74.6	0.60	71.93	0.42
Chemotherapy
No/unknown	21.54		35.16		46.49		52.55
Yes	42.34	0.44	44.13	0.18	47.92	0.03	53.61	0.02
Radiotherapy
No/unknown	28.85		38.14		45.8		53
Yes	48.42	0.42	49.72	0.24	50	0.08	54.05	0.02
Lung metastasis
No	38.7		44.51		48.12		51.58
Yes	22.59	-0.34	33.02	-0.23	45.71	-0.05	58.48	0.14
Bone metastasis
No	31.33		39.55		46.72		53.91
Yes	36.41	0.11	44.54	0.10	49.19	0.05	51.94	-0.04
Brain metastasis
No	32.85		41.08		47.44		53.15
Yes	29.63	-0.07	38.89	-0.04	50	0.05	62.5	0.19

0, 2, 4, 6 refer to the months that patients have survived since initial diagnosis. AFP: α-fetoprotein; d: Standardized differences.